{"nctId":"NCT03871491","briefTitle":"Azithromycin-Prevention in Labor Use Study (A-PLUS)","startDateStruct":{"date":"2020-09-01","type":"ACTUAL"},"conditions":["Maternal Death","Maternal Infections Affecting Fetus or Newborn","Neonatal SEPSIS","Maternal Sepsis During Labor","Neonatal Death","Postpartum Sepsis"],"count":58747,"armGroups":[{"label":"Intervention","type":"EXPERIMENTAL","interventionNames":["Drug: Azithromycin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Azithromycin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pregnant women in labor ≥28 weeks Gestational Age (GA) (by best estimate) with a pregnancy with one or more live fetuses who plan to deliver vaginally in a facility.\n* Admitted to health facility with clear plan for spontaneous or induced delivery.\n* Live fetus must be confirmed via a fetal heart rate by Doptone prior to randomization.\n* ≥18 years of age or minors 14-17 years of age in countries where married or pregnant minors (or their authorized representatives) are legally permitted to give consent.\n* Have provided written informed consent.\n* Pregnant women in labor ≥28 weeks GA (by best estimate) with a pregnancy with one or more live fetuses who plan to deliver vaginally in a facility.\n* Admitted to health facility with clear plan for spontaneous or induced delivery.\n* Live fetus must be confirmed via presence of a fetal heart rate prior to randomization.\n* ≥18 years of age or minors 14-17 years of age in countries where married or pregnant minors (or their authorized representatives) are legally permitted to give consent.\n* Have provided written informed consent \\[Note: written informed consent may be obtained during antenatal care, but verbal re-confirmation may be needed (per local regulations) at the time of randomization\\].\n\nExclusion Criteria:\n\n* Non-emancipated minors (as per local regulations)\n* Evidence of chorioamnionitis or other infection requiring antibiotic therapy at time of eligibility (however, women given single prophylactic antibiotics with no plans to continue after delivery should not be excluded).\n* Arrhythmia or known history of cardiomyopathy.\n* Allergy to azithromycin or other macrolides that is self-reported or documented in the medical record.\n* Any use of azithromycin, erythromycin, or other macrolide in the 3 days or less prior to randomization.\n* Plan for cesarean delivery prior to randomization.\n* Preterm labor undergoing management with no immediate plan to proceed to delivery.\n* Advanced stage of labor (\\>6 cm or 10 cm cervical dilation per local standards) and pushing or too distressed to understand, confirm, or give informed consent regardless of cervical dilation.\n* Are not capable of giving consent due to other health problems such as obstetric emergencies (for example, antepartum hemorrhage) or mental disorder.\n* Any other medical conditions that may be considered a contraindication per the judgment of the site investigator.\n* Previous randomization in the trial.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maternal Death or Sepsis Within 6 Weeks (42 Days) Post-delivery in Intervention vs. Placebo Group.","description":"Maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":null},{"groupId":"OG001","value":"344","spread":null}]}]}]},{"type":"PRIMARY","title":"Intrapartum/Neonatal Death or Sepsis Within 4 Weeks (28 Days) Post-delivery in Intervention vs. Placebo Group","description":"Intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group. This outcome is measured among stillbirths and neonates with 28-day status available born to women randomized. The study includes multiple births so there are more stillbirths and neonates than participants enrolled.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1,540","spread":null},{"groupId":"OG001","value":"1,526","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Sepsis","description":"Maternal sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null},{"groupId":"OG001","value":"339","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Death Due to Sepsis","description":"Maternal death due to sepsis using the Global Network algorithm for cause of death","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Chorioamnionitis","description":"Fever (\\>100.4°F/38°C) in addition to one or more of the following: fetal tachycardia ≥160 bpm, maternal tachycardia \\>100 bpm, tender uterus between contractions, or purulent/foul smelling discharge from uterus prior to delivery.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Endometritis","description":"Fever (\\>100.4°F/38°C) in addition to one or more of maternal tachycardia \\>100 bpm, tender uterine fundus, or purulent/foul smelling discharge from uterus after delivery.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null},{"groupId":"OG001","value":"294","spread":null}]}]}]},{"type":"SECONDARY","title":"Cesarean Wound Infection","description":"Wound infection (Purulent infection of a Cesarean wound with or without fever. In the absence of purulence, requires presence of fever \\>100.4°F/38°C and at least one of the following signs of local infection: pain or tenderness, swelling, heat, or redness around the incision/laceration);","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]}]},{"type":"SECONDARY","title":"Perineal Wound Infection","description":"Wound infection (Purulent infection of a perineal wound with or without fever. In the absence of purulence, requires presence of fever \\>100.4°F/38°C and at least one of the following signs of local infection: pain or tenderness, swelling, heat, or redness around the incision/laceration);","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"188","spread":null}]}]}]},{"type":"SECONDARY","title":"Other Infections","description":"Abdominopelvic abscess (Evidence of pus in the abdomen or pelvis noted during open surgery, interventional aspiration or imaging); Pneumonia (Fever \\>100.4°F/38°C and clinical symptoms suggestive of lung infection including cough and/or tachypnea \\>24 breaths/min or radiological confirmation); Pyelonephritis (Fever \\>100.4°F/38°C and one or more of the following: urinalysis/dip suggestive of infection, costovertebral angle tenderness, or confirmatory urine culture); Mastitis/breast abscess or infection (Fever \\>100.4°F/38°C and one or more of the following: breast pain, swelling, warmth, redness, or purulent drainage). Other bacterial infection.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]}]},{"type":"SECONDARY","title":"Use of Subsequent Maternal Antibiotic Therapy","description":"Use of subsequent maternal antibiotic therapy after randomization to 42 days postpartum for any reason.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7,937","spread":null},{"groupId":"OG001","value":"8,180","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Initial Hospital Length of Stay","description":"Time from drug administration until initial discharge after delivery (time may vary by site).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.8"},{"groupId":"OG001","value":"1.4","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Maternal Readmissions","description":"Maternal readmissions after delivery discharge and within 42 days of delivery","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"192","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Admission to Special Care Units","description":"Maternal admission to special care units","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Unscheduled Visit for Care","description":"Maternal unscheduled visit for care","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1,397","spread":null},{"groupId":"OG001","value":"1,790","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal GI Symptoms","description":"Maternal GI symptoms including nausea, vomiting, and diarrhea and other reported side effects.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Sepsis","description":"Neonatal sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group. This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1,433","spread":null},{"groupId":"OG001","value":"1,407","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Death Due to Sepsis","description":"Neonatal death due to sepsis using the Global Network algorithm for causes of death. This outcome is measured among neonates with 28-day status available born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Other Neonatal Infections","description":"Other neonatal infections (e.g. eye infection, skin infection). This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"763","spread":null},{"groupId":"OG001","value":"798","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Initial Hospital Length of Stay","description":"Neonatal initial hospital length of stay, defined as time of delivery until initial discharge (time may vary by site). This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"2.4"},{"groupId":"OG001","value":"1.5","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Neonatal Readmissions","description":"Neonatal readmissions to facility after delivery discharge and within 42 days of delivery. This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"553","spread":null},{"groupId":"OG001","value":"518","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Admission to Special Care Units","description":"Neonatal admission to special care units. This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"951","spread":null},{"groupId":"OG001","value":"927","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Unscheduled Visit for Care","description":"Neonatal unscheduled visit for care. This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3,223","spread":null},{"groupId":"OG001","value":"3,366","spread":null}]}]}]},{"type":"SECONDARY","title":"Pyloric Stenosis Within 42 Days of Delivery","description":"Pyloric stenosis within 42 days of delivery, defined as clinical suspicion based on severe vomiting leading to death, surgical intervention (pyloromyotomy) as verified from medical records, or radiological confirmation. This outcome is measured among neonates born to women randomized. The study includes multiple births so there are more neonates than maternal participants enrolled.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":14589},"commonTop":["Severe vaginal pain","Vomited within 15 minutes after study drug administration","Feeling faint or dizzy","Severe abdominal or uterine pain","GI symptoms and other reported side effects"]}}}